Hexyon ® (also known as Hexaxim ® or Hexacima ®, depending on the country where marketed) is a thiomersal-free, fully-liquid, ready-to-use hexavalent pediatric vaccine (DTaP-IPV-HepB-Hib). Ī combination of diphtheria toxoid (D), tetanus toxoid (T), and acellular pertussis (aP) or whole-cell pertussis (wP) antigens (DTaP or DTwP) serves as a backbone to which poliovirus, HB virus or Hib antigens are added to produce quadrivalent, pentavalent, and hexavalent vaccines. antigen compatibility, complex manufacturing and quality control processes), multivalent vaccines are of great public health and economic value, as they improve vaccine coverage, reduce costs and potential outbreaks, and allow incorporation of new antigens without increasing the number of injections. Multivalent vaccines are routinely used in Europe and elsewhere against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B (HB), and invasive diseases caused Haemophilus influenzae type b (Hib). Thus, Hexyon ® is a convenient, useful option for vaccination against childhood diseases caused by six major pathogens. However, Hexyon ® offers the convenience of full-liquid, ready-to-use formulation, which may minimize vaccination errors and preparation time. The immunogenicity and safety profile of Hexyon ® was similar to that of several approved vaccines, including Infanrix hexa™. Hexyon ® has a good reactogenicity/safety profile. Coadministration of Hexyon ® with other common childhood vaccines did not affect immune response to any vaccines. Hexyon ® can be used for a mixed primary series of hexavalent-pentavalent-hexavalent vaccines or as a booster in infants primed with Infanrix hexa™ or pentavalent (whole-cell or acellular pertussis) vaccines. It provides durable protection against hepatitis B. ![]() Hexyon ® is highly immunogenic for all its component toxoids/antigens when used as primary and booster vaccine in infants and toddlers, irrespective of vaccination schedule. While the source of HB antigen in Hexyon ® is different from other vaccines, the rest of its valences have been extensively used in other approved vaccines. ThisĪssessment normally takes place in the vaccinator's workplace.Hexyon ® is a fully-liquid, ready-to-use, hexavalent vaccine approved in the EU since 2013 for primary and booster vaccination in infants and toddlers from age 6 weeks against diphtheria, tetanus, pertussis, hepatitis B (HB), poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). Participant - neither IMAC nor local Immunisation Coordinators can arrange this. Arranging a venue to undertake the assessment is the responsibility of the course ![]() This is a requirement for attaining pharmacist or authorised vaccinator status. ![]() These professional groups may still enrol in this course to gain greater understanding of vaccines and immunisation service delivery in Aotearoa/New Zealand. ![]() As prescribers, midwives and medical doctors need not be authorised to administer vaccines. The FLVFC provides information and practical skills related to the safe and effective delivery of vaccines on the National Immunisation Schedule. (Additional requirements to attain authorisation are outlined in the Immunisation Handbook, Appendix 4.) The FLVFC is the coursework component for nurses and pharmacists wishing to become authorised or pharmacist vaccinators. This course combines online learning and assessment with a face-to-face tutorial. To be eligible to complete this course you will need to be employed in a vaccinating role, or moving to a vaccinating role and have (or can arrange) a clinical placement to ensure course completion. This course is currently fully funded by Te Whatu Ora HNZ to support new vaccinators in the workforce.
0 Comments
Leave a Reply. |